Navigation Links
deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
Date:10/28/2008

REYKJAVIK, Iceland, October 28 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it will report its third quarter 2008 financial results in a press release to be issued on Thursday, November 6, after the close of the market in New York. The company will host a live webcast of its conference call to discuss these results and recent operating highlights on Friday, November 7, at 8am EST/1pm GMT.

The webcast can be accessed through the Investors page of deCODE's website, http://www.decode.com, or through http://www.earnings.com. Please log in to the webcast 15 minutes prior to the scheduled start of the call. The call will be archived for at least a week on each site. For those unable to listen to the webcast because of company firewall or other issues, a digitized audio replay will also be available by telephone from approximately 11:30am ET on Friday, November 7 and for one week thereafter. The dial-in replay numbers are: 1-(800)-475-6701 in the U.S., and +1-320-365-3844 for those calling from outside the U.S. The access code is 967723.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts:

deCODE genetics,

Gisli Arnason,

+354-570-1825,

gisli.arnason@decode.is .


'/>"/>
SOURCE deCODE genetics Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
2. deCODE Receives Nasdaq Deficiency Notice Relating to Market Value
3. Researchers decode viral process that prepares cells for HIV infection
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
5. deCODE genetics Announces Second Quarter 2008 Financial Results
6. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results
7. deCODE genetics to Webcast Presentations at Annual R&D Event
8. deCODE genetics to Webcast Presentation at Piper Jaffray Europe Conference
9. deCODE genetics Announces First Quarter 2008 Financial Results
10. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
11. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):